Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05303532 Enrolling by invitation - Cancer Clinical Trials

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

ROSY-D
Start date: April 19, 2022
Phase: Phase 3
Study type: Interventional

The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

NCT ID: NCT05282719 Enrolling by invitation - Clinical trials for Myelodysplastic/Myeloproliferative Neoplasms

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Start date: April 2022
Phase: Phase 2
Study type: Interventional

To explore the efficacy of venetoclax combined with azacytidine in Myelodysplastic / myeloproliferative neoplasms(MDS/MPN), so as to improve the overall survival and treatment status of MDS/MPN patients.

NCT ID: NCT05265091 Enrolling by invitation - Clinical trials for Advanced Solid Tumor

A Study of KL590586 in Patients With Advanced Solid Tumors

Start date: June 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

NCT ID: NCT05225038 Enrolling by invitation - Clinical trials for Pancreatic Neoplasms

Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms

Start date: June 13, 2022
Phase: N/A
Study type: Interventional

Randomized Clinical Trial Investigating Multidimensional Prehabilitation in Pancreatic Surgery for participants with Pancreatic and Periampullary Neoplasms

NCT ID: NCT05214976 Enrolling by invitation - Clinical trials for Advanced Solid Tumors

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Start date: August 12, 2022
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate safety, tolerability and preliminary efficacy of Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel For Injection(Albumin Bound) for advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for advanced malignant tumors of patients.

NCT ID: NCT05198817 Enrolling by invitation - Clinical trials for Advanced Malignant Tumors

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Start date: February 22, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-2002 injection monotherapy and in combination with other anti-cancer therapy for advanced malignant tumors of patients. To explore the reasonable dosage of SHR-2002 injection monotherapy and dosage regimen of combination therapy for advanced malignant tumors of patients.

NCT ID: NCT05173805 Enrolling by invitation - Clinical trials for Advanced Solid Tumor

Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation

Start date: January 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-15293 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose of YL-15293 and obtain the preliminary efficacy information of patients with advanced solid tumors with KRAS mutation.

NCT ID: NCT05111509 Enrolling by invitation - Clinical trials for Neuroendocrine Tumor Grade 2

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Start date: August 22, 2022
Phase: Early Phase 1
Study type: Interventional

This is a first in man study to determine if [203Pb]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing [212Pb]-based alpha radiation therapy in neuroendocrine therapy.

NCT ID: NCT05075759 Enrolling by invitation - Clinical trials for Malignant Solid Neoplasm

Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer

SALSA
Start date: June 6, 2022
Phase: N/A
Study type: Interventional

This clinical trial evaluates several behavioral interventions for the improvement of physical activity in cancer patients. Childhood and adolescent/young adult cancer survivors have been reported to have poor diet quality and rarely meet recommended physical activity guidelines. This trial aims to see whether a tailored intervention based on self-determination theory may help to improve physical activity and dietary change.

NCT ID: NCT05067413 Enrolling by invitation - Clinical trials for Rectal Neoplasms Malignant

A Study on the Efficacy of a Novel Approach to Achieving Laparoscopic Distal Rectal Transection for Rectal Cancers

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The wide application of ISR and DST has greatly improved the anal preservation rate for low rectal cancers, but the technical difficulty has also been obviously increased because of the limited pelvic space. Although many scholars have tried to solve this problem, all the methods have failed to fundamentally solve the problem of "the oblique dissection" of the distal rectum. To solve the problem above, the director of this clinical trial has explored a new distal rectal resection method-- transanterior obturator nerve gateway approach. The purpose of this clinical trial is to prospectively collect and compare data on the patients' perioperative variables and postoperative functional and oncological outcomes of this novel approach with the traditional approach to confirm the safety and feasibility of this novel approach and its advantages over the traditional approach.